ClinicoEconomics and Outcomes Research (Sep 2021)
Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization
Abstract
Richard F Pollock,1 Fabien Colaone,2 Suki Shergill,2 Victoria K Brennan,2 Ion Agirrezabal2 1Health Economics and Outcomes Research, Covalence Research Ltd, London, UK; 2Global Health Economics, Pricing, Reimbursement & Market Access, Sirtex Medical United Kingdom Ltd, London, UKCorrespondence: Richard F PollockCovalence Research Ltd, 51 Hayes Grove, London, SE22 8DF, UKTel +44 20 8638 6525Email [email protected] and Aims: Quality of life is among the most important considerations in the treatment of hepatocellular carcinoma (HCC), arguably second only to overall survival. Measuring and modeling patient quality of life is also crucial in the evaluation of the cost-effectiveness of health interventions. In the present study, we aimed to identify cost-utility analyses comparing selective internal radiation therapy (SIRT) with systemic therapy in patients with unresectable HCC and to compare the modeled incremental quality of life differences between the two therapies.Methods: A systematic literature review was conducted. PubMed, EMBASE, the Cochrane Library, and health technology assessment agency websites were searched to identify cost–utility studies of SIRT versus systemic therapies in the treatment of HCC. Key characteristics of the studies, modeled populations and incremental quality of life outcomes were extracted from the included studies.Results: The systematic literature review retrieved 1140 studies, of which four were ultimately included. Hand searches then identified two distinct analyses, and an updated version of one of the four studies identified initially. From these seven studies, 18 analyses were included. Analyses using data from the overall trial populations reported incremental quality-of-life estimates spanning − 0.09 to +0.28 quality-adjusted life years (QALYs), with that range expanding to − 0.09 to +0.60 QALYs when also considering post hoc sub-group analyses.Conclusion: The wide range of incremental QALYs, with substantial differences between overall trial populations and subgroups, illustrates the impact that the choice of target population may have on the relative quality of life outcomes of the compared interventions, which may in turn affect clinical decision-making. The small differences also highlight both the importance of reporting measures of dispersion around the findings, and the limitations of the incremental cost-effectiveness ratio (ICER) for assessing the relative cost-effectiveness of interventions that are predicted to result in similar quality-of-life outcomes.Keywords: hepatocellular carcinoma, quality of life, brachytherapy
